Taylor Cottrill Erickson & Associates Inc. Sells 25 Shares of Illumina, Inc. (ILMN)

Taylor Cottrill Erickson & Associates Inc. decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,980 shares of the life sciences company’s stock after selling 25 shares during the period. Taylor Cottrill Erickson & Associates Inc.’s holdings in Illumina were worth $517,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Advocacy Wealth Management Services LLC bought a new position in Illumina during the first quarter worth $102,000. Advisory Services Network LLC bought a new position in Illumina during the first quarter worth $117,000. Gemmer Asset Management LLC boosted its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Patten Group Inc. boosted its position in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. boosted its position in Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares during the last quarter. 93.91% of the stock is currently owned by hedge funds and other institutional investors.

Illumina, Inc. (NASDAQ:ILMN) opened at 189.32 on Friday. The company has a market cap of $27.64 billion, a P/E ratio of 37.99 and a beta of 0.83. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95. The stock’s 50 day moving average price is $181.43 and its 200 day moving average price is $174.88.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter last year, the firm earned $0.86 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/illumina-inc-ilmn-shares-sold-by-taylor-cottrill-erickson-associates-inc-updated-updated.html.

A number of research firms have recently weighed in on ILMN. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective on the stock in a research report on Wednesday, August 9th. Barclays PLC reaffirmed an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a research report on Wednesday, August 9th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Cowen and Company reaffirmed an “outperform” rating and set a $200.00 price objective on shares of Illumina in a research report on Wednesday, August 2nd. Finally, Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. Illumina presently has an average rating of “Hold” and an average target price of $177.01.

In other Illumina news, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $175.53, for a total transaction of $2,632,950.00. Following the completion of the sale, the director now owns 534,176 shares of the company’s stock, valued at $93,763,913.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Omead Ostadan sold 1,672 shares of the firm’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $172.73, for a total value of $288,804.56. Following the sale, the executive vice president now directly owns 26,242 shares of the company’s stock, valued at approximately $4,532,780.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 154,010 shares of company stock valued at $27,840,615. Insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit